Green A, Newton R, Smith D, Tuffaha H, Galvao D, Heathcote P
BMJ Open. 2024; 14(3):e084412.
PMID: 38521521
PMC: 10961537.
DOI: 10.1136/bmjopen-2024-084412.
Papadopoulos E, Leach H, Tomlinson G, Durbano S, Danyluk J, Sabiston C
Support Care Cancer. 2022; 30(11):9011-9018.
PMID: 35948848
DOI: 10.1007/s00520-022-07300-2.
Gentili C, McClean S, McGeagh L, Bahl A, Persad R, Harcourt D
Psychooncology. 2022; 31(11):1958-1971.
PMID: 35833603
DOI: 10.1002/pon.6001.
Ogawa S, Hasegawa A, Makabe S, Onagi A, Matsuoka K, Kayama E
Res Rep Urol. 2022; 14:39-48.
PMID: 35223660
PMC: 8865904.
DOI: 10.2147/RRU.S342063.
Lambert S, Duncan L, Culos-Reed S, Hallward L, Higano C, Loban E
Curr Oncol. 2022; 29(2):785-804.
PMID: 35200566
PMC: 8871005.
DOI: 10.3390/curroncol29020067.
Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study.
Sanchez-Martinez V, Buigues C, Navarro-Martinez R, Garcia-Villodre L, Jeghalef N, Serrano-Carrascosa M
Life (Basel). 2021; 11(3).
PMID: 33802213
PMC: 8000211.
DOI: 10.3390/life11030227.
Androgen receptors in areas of the spinal cord and brainstem: A study in adult male cats.
Coolen R, Cambier J, Spantidea P, van Asselt E, Blok B
J Anat. 2021; 239(1):125-135.
PMID: 33619726
PMC: 8197961.
DOI: 10.1111/joa.13407.
Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2).
Algotar A, Kumar R, Babiker H, Dougherty S, Hsu C, Chow H
Contemp Clin Trials Commun. 2021; 21:100701.
PMID: 33511299
PMC: 7815988.
DOI: 10.1016/j.conctc.2021.100701.
Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis.
Yiannopoulou K, Anastasiou A, Kontoangelos K, Papageorgiou C, Anastasiou I
Curr Urol. 2021; 14(4):169-177.
PMID: 33488334
PMC: 7810213.
DOI: 10.1159/000499242.
Prostate Cancer Survivors' and Caregivers' Experiences Using Behavior Change Techniques during a Web-Based Self-Management and Physical Activity Program: A Qualitative Study.
Hallward L, Chemtob K, Lambert S, Duncan L
J Clin Med. 2020; 9(10).
PMID: 33050578
PMC: 7601492.
DOI: 10.3390/jcm9103244.
Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
Shin D, Shim S, Kim C
PLoS One. 2020; 15(6):e0234264.
PMID: 32542009
PMC: 7295190.
DOI: 10.1371/journal.pone.0234264.
An Educational Program to Help Patients Manage Androgen Deprivation Therapy Side Effects: Feasibility, Acceptability, and Preliminary Outcomes.
Wibowo E, Wassersug R, Robinson J, Santos-Iglesias P, Matthew A, McLeod D
Am J Mens Health. 2020; 14(1):1557988319898991.
PMID: 32024430
PMC: 7005977.
DOI: 10.1177/1557988319898991.
hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.
Fraser J, Sutton J, Tazayoni S, Bruce I, Poole A
Sci Rep. 2019; 9(1):19076.
PMID: 31836808
PMC: 6911083.
DOI: 10.1038/s41598-019-55665-y.
"Kicked out into the real world": prostate cancer patients' experiences with transitioning from hospital-based supervised exercise to unsupervised exercise in the community.
Schmidt M, Ostergren P, Cormie P, Ragle A, Sonksen J, Midtgaard J
Support Care Cancer. 2018; 27(1):199-208.
PMID: 29931489
DOI: 10.1007/s00520-018-4306-y.
A systematic review of physical activity-based behaviour change interventions reaching men with prostate cancer.
Finlay A, Wittert G, Short C
J Cancer Surviv. 2018; 12(4):571-591.
PMID: 29770953
DOI: 10.1007/s11764-018-0694-8.
The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
Kim J, Park J, Ham W
Investig Clin Urol. 2017; 58(5):307-316.
PMID: 28868501
PMC: 5577326.
DOI: 10.4111/icu.2017.58.5.307.
Development and Initial Validation of the Novel Scale for Assessing Quality of Life of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Dun Y, Liu H, Yu L, Li Q, Zhang X, Tang X
Chin Med J (Engl). 2017; 130(17):2082-2087.
PMID: 28836552
PMC: 5586177.
DOI: 10.4103/0366-6999.213416.
Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
Chung S, Kao L, Lin H, Xirasagar S, Huang C, Lee H
PLoS One. 2017; 12(3):e0173266.
PMID: 28253340
PMC: 5333913.
DOI: 10.1371/journal.pone.0173266.
Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
Owen P, Daly R, Livingston P, Fraser S
Prostate Cancer Prostatic Dis. 2017; 20(2):137-145.
PMID: 28117386
PMC: 5508230.
DOI: 10.1038/pcan.2016.69.
What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product.
Rot I, Wassersug R, Walker L
Transl Androl Urol. 2016; 5(2):235-47.
PMID: 27141453
PMC: 4837317.
DOI: 10.21037/tau.2016.03.06.